Kymera Therapeutics, Inc. Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc.

KYMR

Rank in Stocks #2255
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to... Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins. The company's pipeline features several programs, including the IRAK4 program, currently in Phase I clinical trials, which targets various immunology-inflammation disorders such as hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, generalized pustular psoriasis, and rheumatoid arthritis. Additionally, Kymera is advancing its IRAKIMiD program, designed to address MYD88-mutated diffuse large B cell lymphoma. Other key programs include the STAT3 program, focused on hematological malignancies, solid tumors, autoimmune diseases, and fibrosis, as well as the MDM2 program, which is also aimed at hematological malignancies and solid tumors. The company was founded in 2015 and maintains its headquarters in Watertown, Massachusetts.
Share Price
$107.95
Market Cap
$8.88B
Change (1 day)
3.03%
Change (1 year)
80.43%
Country
US
Trade Kymera Therapeutics, Inc. (KYMR)

Category

Healthcare
Dividend yield history for Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (stock symbol: KYMR) dividend yield (TTM) as of 2023-12-31: 0.00%
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Kymera Therapeutics, Inc. (KYMR) from 2018 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
2026 (TTM) 0.00% 0.00%
2024 0.00% 0.00%
2023 0.00% 0.00%
2022 0.00% 0.00%
2021 0.00% 0.00%
2020 0.00% 0.00%
2019 0.00% 0.00%
2018 0.00% 0.00%
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.00%
US
0.00%
US
2.17%
AU
0.00%
CH
0.00%
NL